Significant evidence of a dose‐dependent effect on the relevant amyloid (amyloid PET and cerebrospinal fluid [CSF] Aβ) and tau biomarkers (CSF p‐tau, CSF t‐tau, and plasma p‐tau) reported elsewhere support the conclusion that aducanumab modifies the underlying pathophysiology of AD.14 Here, MAPT is linked to Alzheimer disease.